Objective To develop the clinical practice guidelines for the management of medication adherence to highly active antiretroviral therapy (HAART) in China. Methods The development methods included qualitative interview of 31 stakeholders, questionnaire survey of 423 PLHIV, adaptation of 30 clinical practice guidelines related to AIDS care, and overviews of reviews of 44 systematic reviews/Meta-analysis. Results 10 clinical practice guidelines and 10 systematic reviews/Meta-analysis were included. The clinical practice guidelines for the management of HAART were formed. Conclusions The formed clinical practice guidelines showed better applicability and higher general quality. It is recommended to use the guidelines in AIDS care.

Hepatic fibrosis is an intrinsic reaction of chronic liver injury, and hepatic stellate cells play an important role in the occurrence and development of hepatic fibrosis.Traditional drugs for the treatment of liver fibrosis have disadvantages such as low solubility and no liver targeting.Nowadays, with the con¬tinuous development of nanotechnology and nanomedicine, nano- drugs have been gradually applied to the development and re¬search of liver fibrosis with their characteristics of safety, stabili¬ty, sustained release and targeting.In recent years the main fo¬cus of nano-dnigs on the mechanism of liver fibrosis is hepatic stellate cells.It may be the mainstream direction of future anti- liver fibrosis research to modify inorganic and organic nanoparti- cles with drug-carrying properties to achieve the treatment of liv¬er fibrosis by targeting hepatic stellate cells.This article reviews the classification and application of some new nanomedicines in the treatment of hepatic fibrosis based on the new nanomedicines acting on hepatic stellate cells.